CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Binghe Xu; Ying Fan

doi:10.1016/S1470-2045(20)30757-9

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Binghe Xu
, Ying Fan

Health Science Center

Chinese Academy of Medical Sciences

Research output: Contribution to journal › Comment/debate

13 Scopus citations

Original language	English
Pages (from-to)	159-160
Number of pages	2
Journal	The Lancet Oncology
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/S1470-2045(20)30757-9
State	Published - Feb 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1470-2045(20)30757-9

Cite this

@article{dc2e7b23f32f4ad58650639822e3201d,

title = "CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?",

author = "Binghe Xu and Ying Fan",

year = "2021",

month = feb,

doi = "10.1016/S1470-2045(20)30757-9",

language = "英语",

volume = "22",

pages = "159--160",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - CDK4/6 inhibition in early-stage breast cancer

T2 - how far is it from becoming standard of care?

AU - Xu, Binghe

AU - Fan, Ying

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85099935945

U2 - 10.1016/S1470-2045(20)30757-9

DO - 10.1016/S1470-2045(20)30757-9

M3 - 评论/辩论

C2 - 33460573

AN - SCOPUS:85099935945

SN - 1470-2045

VL - 22

SP - 159

EP - 160

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

UN SDGs

Access to Document

Other files and links

Cite this